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Abstract 
β-Adrenergic blockers appear to be effective in the management of verbal aggression, physical 
aggression, or self-injurious behavior associated with mental retardation and other developmental disorders. 
However, methodological limitations of the available studies make it difficult to judge the value of these 
treatments. Optimal doses for treating patients with mental retardation or developmental disorders appear 
lower than described in the general psychiatric literature, so low doses of β-blockers may be preferred in such 
patients with abnormal brain development. Children and adolescents with mental retardation or 
developmental disorders appear to respond to particularly low doses (e.g., below propranolol 150 mg daily). 
Propranolol is recommended for central blockade, and nadolol is recommended for peripheral blockade. 
Most β receptors in the brain (except cerebellum) seem to be β1 (cardiac type), but it is not clear that central 
blockade is required for psychotropic effects. Interim suggestions for empirical trials are offered, and rating 
scales and other measurement approaches are discussed. Since evidence supporting the efficacy of 
β-blockers in mental retardation or developmental disorders in children and adolescents is not definitive, the 
clinician is advised to consider designing an empirical trial for each patient, utilizing pre- and postmedication 
measures, when conventional treatments have been unsuccessful. 
Introduction 
Neuroluptic medications comprise the most common form of psychopharmacological 
management of patients with mental retardation (MR) and other developmental disorders (DD), 
and are often used for symptomatic control of aggressive and self-injurious behavior (Aman and 
Singh 1988). Given the potential of these drugs to produce tardive dyskinesia, neuroleptic 
malignant syndrome, and other side effects, the emerging awareness of the promising clinical 
utility of the β-adrenergic blockers is most welcome. 
The use of β-blockers in general psychiatry has been discussed in a recent review by Neppe 
(1989), and their psychopharmacological use in children and adolescents has been reviewed by 
Coffey (1990). This article will review (1) the pharmacology of β-blockers, (2) the use of 
β-blockers in general psychiatry, (3) their use in MR/DD, especially in children, (4) suggested 
guidelines for clinical use in children and adolescents with MR/DD, and (5) the potential role of 
empirical trials of β-blockers for children with MR/DD. 
Pharmacology 
β-Adrenergic receptors are found in both neural and nonneural tissues. These receptors can 
be activated by direct sympathetic nervous transmission and by circulating endocrine 
catecholamines (norepinephrine, epinephrine, and to a lesser extent dopamine). Both types of 
activation are involved in the general alarm ("fight or flight") reaction to stress, β1 receptors are 
found in the heart and brain, and β2 receptors are mainly vascular, bronchial, and gastrointestinal. 
In the central nervous system, β-receptors can be found in the medulla, cerebellum, extrapyramidal 
system, hypothalamus, limbic forebrain, pineal gland, and neocortex (Conwayetal. 1978, Palacios 
and Kuhar 1980). Most of these are probably β1, except that the cerebellum has mainly β2 
receptors. 
There are a wide variety of β-adrenergic blocker agents. The lipid-soluble (lipophilic) 
drugs cross the blood-brain barrier (propranolol, metroprolol, alprenolol, and pindolol), and the 
water-soluble (hydrophilic) drugs do not cross as readily (atenolol, nadolol, timolol). Only the 
lipid-soluble agents are believed to provide significant central blockade. However, it is not at all 
clear that central blockade is necessary for psychiatric benefit in treating anxiety or aggression 
(e.g., Alpert et al. 1990, Ratey et al. 1987a,b). The psychotropic effects may be largely or even 
completely based on peripheral effects. Also, some brain structures, such as the pineal and 
periventricular nuclei, do not have a blood-brain barrier and are exposed to circulating hydrophilic 
agents. 
The doses needed for central β1 blockade appear considerably higher than required for 
peripheral β-blockade (e.g., Hayes and Schulz 1983). 
Propranolol (Inderal or generic) and nadolol (Corgard) block both β1 and β2 receptors 
nonselectively. Atenolol (Tenormin) and metaprolol (Lopressor) are selective β1 blockers. An 
ideal central β-blocker would presumably be both β1-specific (cardioselective) and lipophilic. 
Metaprolol (Lopressor) has these features, but has not been well studied for treatment of 
behavioral problems. 
Propranolol is the best studied of the β-blockers. Approximately two thirds of propranolol 
is metabolically cleared on first pass through the liver, so that less than 40% is bioavailable (Wood 
et al. 1978). Hepatic metabolism produces two active metabolites, hydroxypropranolol and 
propranolol glycol, the latter having some antiepileptic effect (Fitzgerald and O'Donnell 1971, 
Shand 1975). The half-life of propranolol is about 4 hours. Therefore, multiple daily doses are 
needed. 
Nadolol and some other β-blockers have longer half-lives (over 20 h for nadolol) and 
require less frequent dosing, at least for cardiovascular indications. The peripherally active 
hydrophilic β-blockers are excreted by the kidney without hepatic degradation. 
Blockade of β1 receptors decreases the heart rate; decreased chronotropic and inotropic 
effects can diminish cardiac output and thereby decrease blood pressure. Blockade of β2 receptors 
in the bronchioles increases airway resistance; this can cause bronchospasm in patients with 
asthma, but is not a problem for nonasthmatic patients (Hayes and Schulz 1987). β-blockade can 
also interfere with glycogenolysis during hypoglycemia, necessitating caution in diabetics or other 
patients prone to hypoglycemia. Central side effects can include toxic psychosis, vivid dreams, 
insomnia, visual or tactile hallucinations (Conway et al. 1978), lightheadedness, fatigue, and 
depression (Neppe 1989). 
Propranolol can also antagonize central serotonin (5HT) receptors in addition to 
β-adrenergic receptors (Weinstock and Weiss 1980), particularly 5HT, receptors (Hoyer 1988). 
Additionally, propranolol has a membrane-stabilizing effect at high doses (Hayes and Schulz 
1983). 
Important drug interactions with other lipid-soluble agents (including antidepressants, 
neuroleptics, benzodiazepines) result from competition for the cytochrome P450 enzyme system. 
Adding propranolol to any of these psychotropic medications will yield higher circulating levels of 
both drugs, sometimes up to fivefold of the original drug levels (Silber et al. 1981). 
General Psychiatric Use of Beta Blockers 
In the late 1960s, propranolol was reported to be beneficial for some anxiety symptoms 
apparently associated with " β-adrenergic hypersensitivity" (Granville-Grossman and Turner 
1966). Soon, clinicians tried β-blockers for intractable cases of many disorders, resulting in a 
considerable list of psychiatric diagnoses for which β-blockers have been claimed to be helpful. 
Anxiety and anxiety disorders 
The effect of β-blockers on anxiety is perhaps the best studied of their psychiatric uses. 
Besides uncontrolled open trials, Neppe (1989) counted 15 controlled studies (11 with 
propranolol) which he felt "established" their efficacy in treating anxiety, at least in regard to 
"somatic anxiety." Cardiorespiratory anxiety syndromes often seem to benefit from β-blockers, 
even when added to partially successful benzodiazepine treatment. In contrast, Neppe (1989), after 
reviewing the literature, concluded that "psychic anxiety" without significant somatic involvement 
seems not to be affected by β-blockers. β-blockers do not appear to be a treatment of first choice 
for anxiety disorders, but they can provide a good second line or adjunct (Gualtieri et al. 1983). 
Interestingly, the dextroisomer of propranolol, which has little β-blocking effect but the 
same membrane-stabilizing activity as the racemic mixture, lacks the antianxiety effect, 
suggesting that the β-blockade rather than membrane stabilization is the mechanism relevant to 
anxiety disorders (Bonn and Turner 1971). 
Stress-related reactions are often hyperadrenergic states, β-blockers have been reported 
helpful for posttraumatic stress disorder (PTSD) in children (Famularo et al. 1988) as well as for 
chronic and acute situational stress reactions in adults. Neppe (1989) suggests that much lower 
doses may be appropriate for treating reactive stress than for treating anxiety disorders, and 
mentions the efficacy of a p.r.n. dose before stressful situations such as examinations and public 
speaking. 
Panic disorder, which also entails a hyperadrenergic state, might be expected to be a 
natural candidate for treatment with β-blockers, so it is surprising that the limited available 
literature does not support the efficacy of β-blockers in controlled studies (Neppe 1989). Further, 
Gorman et al. (1983) reported that β-adrenergic blockers do not ameliorate lactate-induced panic 
symptoms, as do antidepressant drugs, which are an established treatment for panic disorder. 
Psychoses 
The studies of β-blockers in schizophrenia and other psychoses have produced mixed 
results. In general, propranolol is found to be clearly beneficial only when combined with a 
neuroleptic (e.g., Eccleston et al. 1985, Myers et al. 1981). It is not likely that the direct 
mechanism of antipsychotic action here is dopamine antagonism, since propranolol does not 
elevate serum prolactin as do the antidopaminergic neuroleptics (Hansenn et al. 1980). Another 
possible mechanism could be serotonin antagonism (Lader 1988). The reported efficacy of 
D-propranolol added to haloperidol (Manchanda and Hirsch 1986) suggests that the mechanism 
may involve either membrane stabilization or a propranolol-neuroleptic drug interaction that raises 
neuroleptic blood levels. The entire effect may be explained by the tendency of propranolol to 
increase circulating levels of neuroleptics, but the combination of a β-blocker and a moderate dose 
of a neuroleptic drug sometimes helps when a large dose of a neuroleptic alone did not (Alpert et 
al. 1990). 
When effective for psychosis, β-blockers must be used in much higher doses than for other 
indications. For example, schizophrenic psychosis has been treated with doses of propranolol from 
500 mg (Yorkston et al. 1977) to 1900 mg (Lindstrom and Persson 1980), and manic psychosis has 
been treated with 2000-3000 mg daily (Emrich et al. 1979). This high-dose requirement suggests 
that β-blockers are acting centrally rather than peripherally (see Neppe 1989). Such high doses 
have been reported to cause serious side effects, including delirium, gastrointestinal symptoms, 
and paradoxical acute hypertension (Hayes and Schulz 1983). The improvements reported with 
propranolol generally have been in negative symptoms such as poor socialization, emotional 
withdrawal, and anergia, as well as on agitation, assaultiveness, and irritability, rather than on 
hallucinations or delusions. 
Aggression 
The "fight" component of the "fight or flight" response may be expressed in the behavioral 
spectrum of aggression, rage, and hostility, and often is found in such disorders as intermittent 
explosive disorder, episodic discontrol, or "organic aggressive syndromes." These symptoms have 
been reported to respond to high doses of β-blockers in adults (e.g., Yudofsky et al. 1981) and 
children (e.g., Kuperman and Stewart 1987, Sims and Galvin 1990, Williams et al. 1982). 
Reviewing the available studies across the age span, Volavka (1988) found an 86% rate of 
clinically successful responses, but noted that only one study with 9 patients was controlled. 
A mechanism in the central nervous system (CNS) has been proposed that involves the 
septohippocampal adrenergic system (Neppe 1989). However, the reported success of nadolol, a 
hydrophilic β-blocker that does not readily enter the CNS, suggests that the mechanism may be 
peripheral (Alpert et al. 1990, Ratey et al. 1987). 
Neppe (1989) cautions that a high dosage must be administered for several weeks to 
produce results in treating aggression. The need for a prolonged trial may suggest a mechanism 
involving changes in receptor sensitivity or regulation. 
Despite the equivocal state of the literature, there is enough data to conduct empirical 
clinical trials in individual cases of aggression unresponsive to more conservative treatments, 
especially if there is some indicator of brain damage such as acute brain trauma (Elliott 1977) or 
mental retardation (Kuperman and Stewart 1987). 
Self-injurious behavior is a special category of aggression. Luchins and Dojka (1989) 
report that self-directed aggression and outwardly directed aggression are similarly responsive to 
β-blockade. 
Other uses of ß-blockers 
Substance Withdrawal. 
Withdrawal symptoms from alcohol and many other drugs involve hyperadrenergic states 
that might be expected to be at least partially alleviated by β-blockers. The literature now shows 
only equivocal clinical results (Carlsson 1976, Carlsson and Johansson 1971, see Neppe 1989), but 
this deserves further exploration in view of the possibility that β-blockers could provide anxiety 
relief without dependency, sedation, or abuse potential. 
Tremor. 
β-blockers have been reported to benefit benign essential tremor, lithium-induced tremor, 
parkinsonian tremor, and tremor associated with anxiety (e.g., Jefferson 1974, Neppe 1989). It is 
not clear whether the mechanism of action for managing tremor is central or peripheral. 
Akathisia. 
Preliminary studies suggest possible benefit for akathisia, but this is not yet firmly 
established (Adler et al. 1985, 1986, Lipinski et al. 1984, see Neppe 1989). Alpert et al. (1990) 
report an association between akathisia improvement and aggression score improvement when 
nadolol was added to a neuroleptic. The benefit of nadolol suggests a peripheral mechanism 
underlying the effects on both aggression and akathisia, possibly through a reduction in general 
arousal. 
Migraine headache and other neurological conditions 
β-Blockers are well-established for use in the prevention of migraine, presumably acting 
through direct vascular effects or relief of anxiety. There are reports of benefit in narcolepsy, 
phantom limb pain, stuttering, compulsive water drinking, and tardive dyskinesia (Neppe 1989). 
Usage in Mental Retardation 
Although older surveys rarely mention the use of β-blockers in the MR/DD population 
(Aman and Singh 1988), more recent surveys suggest "pockets" within this clinical population 
where β-blockers are used fairly frequently. For example, the Ohio Legal Rights Service found 
that 13.5% of residents in one developmental center were prescribed β-blockers (Johnson and 
Skinner 1986). 
We concluded a systematic search of all clinical reports of the use of β-blockers for 
managing behavior disorders in persons with mental retardation or developmental disorders. The 
search entailed a computer database retrieval of all relevant publications in English, as well as an 
examination of recent issues of journals specializing in psychopharmacology, mental retardation, 
or developmental disorders. 
Eleven publications were identified that reported empirical data on the effects of β-blocker 
in samples which contained a substantial representation (at least 1/3) of persons with mental 
retardation or developmental disorders (see Table 1). Findings are presented for the entire sample 
and separately for the subjects with MR, when possible. Most of the patients were treated for 
impulsive physical aggression, verbal aggression, or self-injurious behavior. The mean doses of 
propranolol ranged from 120 mg/day (Ratey et al. 1986) to 214 mg/day (Ratey et al. 1987a, 
1987b). As pointed out by Ratey et al. (1986), this range is markedly lower than doses reported in 
some studies of nonretarded psychiatric patients, in which large doses of propranolol (> 520 
mg/day) were needed for efficacy (Greendyke et al. 1984, Shepard 1979, Yudofsky et al. 1981). 
A high positive response rate was reported, both for the entire group of subjects (78% 
positive) and for patients with MR (81%). In individuals with MR, therapeutic changes were seen 
principally in verbal aggression, physical aggression, and self-injurious behavior. The latency of 
response was reported to vary from a few days ("almost overnight" in Jenkins and Maruta 1987) to 
up to 6 weeks (Ratey et al. 1987b). 
In two studies, nadolol was used successfully in place of propranolol. In one case, 
substitution was made because of a patient's refusal to take propranolol (Polakoff et al. 1986). In 
the other study, the reason was the convenience of dosing with the longer half-life of nadolol 
(Ratey et al. 1987a,b). Since nadolol is thought to have a predominantly peripheral action, some 
workers have speculated that β-blockers act by "soothing" and "calming" peripheral arousal 
mechanisms, at least in some patients with MR (Polakoff et al. 1986, Ratey et al. 1987b). 
One report looked at cardiovascular measures as potential predictors of drug response 
(Kuperman and Stewart 1987). Although the blood pressure changes appeared to be unrelated to 
behavioral changes, the positive behavioral responders were less likely to show bradycardia with 
propranolol. 
The strong suggestion of efficacy of the β-blockers for reducing aggression in patients 
with mental retardation or developmental disorders must be tempered by several limitations in the 
data. Foremost, none of these studies employed standard precautions such as contrast groups, 
placebo, or double-blind controls. Second, the subjects varied markedly in age, psychiatric 
diagnosis, and intellectual level, both within and across studies. Third, β-blockers were given in 
conjunction with other psychotropic drugs, usually neuroleptic drugs, in all of the studies. This is 
scientifically problematic: since β-blockers tend to increase the blood levels of neuroleptics, some 
of the changes observed could have been due to enhanced neuroleptic levels rather than the 
β-blocker. (It may be noted that, in the vast majority of cases, the doses of adjunctive neuroleptics 
were able to be reduced during propranolol treatment.) Fourth, only 4 of the 11 studies employed 
some objective measures to assess change in aggression, and none used such indices to assess pre- 
to postmedication effects for all subjects. This lack of objective measurements undermines 
confidence in the findings. Finally, it should be noted that most of these were case reports or 
retrospectively gathered patient data; the well-known tendency to publish successes rather than 
failures may have biased this early literature. Ruedrich et al. (1990), who independently 
conducted an appraisal of this literature, also commented on some of these issues. 
Despite these major limitations, there is enough evidence to warrant prospective 
controlled trials of the β-blockers in the treatment of physical or verbal aggression or 
self-injurious behavior in patients with mental retardation or developmental disorders. Indeed, 
this should be a high priority for the field. In view of the reports of efficacy of nadolol, it would 
also be sensible to conduct trials comparing propranolol and nadolol to determine whether the 
mechanism is related to a peripheral action, a central action, or a combination. It may be 
worthwhile to continue to look for predictors of a positive behavorial response. As suggested by 
Kuperman and Stewart (1987), cardiovascular measures may warrant special attention in this 
respect. 
Recommendations for Clinical Use of β-Blockers in Children and Adolescents with MR/DD 
Of the 11 reports listed in Table 1 on ß-blockers used in the treatment of patients with 
mental retardation or developmental disorders, only three studies included préadolescent children 
and one additional study included
 
 
adolescents. These few studies are too limited to draw databased distinctions between 
(3-blocker treatment of adults and treatment of children and adolescents with mental 
retardation or developmental disorders. Two tentative observations, about dosage and 
cardiovascular monitoring, may be ventured. 
As noted above, the dosage for patients of all ages with mental retardation or 
developmental disorders seems less than that recommended for adults with normal IQ. It is 
not clear whether the organic damage, a difference in brain functioning, the amount of 
brain substrate, the type of target symptom, the pattern of comorbid disorders or concurrent 
symptoms, or some other factor is responsible for this apparent IQ-related difference in 
drug response. Furthermore, the daily doses recommended by Coffey (1990) for normal IQ 
children (10-120 mg propranolol) and adolescents (20-300 mg propranolol) are also less 
than for adults with normal IQ, even after correction for body weight. Presumably, children 
with mental retardation or developmental disorders might be expected to require the lowest 
doses of all. Table 1 provides a small amount of support for this expectation. The six 
reports that included no adolescents or children used a mean daily dose of 210 mg 
propranolol. The four studies that included adolescents or children used a mean dose of 150 
mg. The one study that focused on younger children (≤ age 14) used a mean dose of 99 mg 
propranolol. It would seem appropriate to try low dosages of β-blockers in children with 
MR/DD before trying more conventional doses. 
A minor adjustment may also be considered in the cardiovascular monitoring of 
young patients on ß-blockers. Although a pulse rate of 50/min is considered safe for adults, 
Coffey (1990) recommends keeping pulse rates above 60/min in children. This 
undoubtedly includes children with mental retardation or developmental disorders. Blood 
pressure, on the other hand, is normally lower in children than adults, so blood pressure can 
probably be safely maintained at a slightly lower level in children. 
Practical guidelines 
Since data on the use of ß-blockers in children and adolescents with mental 
retardation or developmental disorders are rather sketchy, the following clinical 
suggestions are abstracted from both the child and the general psychiatric literature, and 
mainly from clinical guidelines offered by Williams et al. (1982), Ayd (1985), Ratey et al. 
(1986), Kuperman and Stewart (1987), Neppe (1989), and Coffey (1990): 
1. By history and physical examination (and laboratory tests as needed), exclude patients 
with significant cardiorespiratory pathology (asthma, congestive heart failure, 
angina), insulin-dependent diabetes, severe vascular disease, severe renal disease, and 
hyperthyroidism. Family medical history of diabetes and mood disorder should be 
obtained. Informed consent needs to mention the relative novelty of the treatment. 
2. A ß-blocking agent may be the treatment of choice for aggression, hostility, or rage 
associated with concussion or acute encephalitis. 
3. An empirically conducted clinical trial can be justified for managing (a) self-directed 
aggression or outwardly directed violence (Luchins and Dojka 1989), (b) aggressive 
behavior in a child or adolescent with brain dysfunction, such as mental retardation or 
developmental disorders (Kuperman and Stewart 1987), and (c) possibly 
stimulant-resistant cases of attention-deficit hyperactivity disorder with conduct 
disorder. 
4. Except in special cases (such as asthmatic patients), it is advisable to use a 
noncardioselective agent without intrinsic sympathomimetic activity. At this time, 
propranolol (Inderal or generic) is the most commonly used centrally active 
ß-blocker, and nadolol. (Corgard) is the preferred peripherally active agent. 
5. A prospective behavioral monitoring system should be selected before initiation of 
the drug. Behavioral observations, counts, or ratings should be obtained at baseline 
and repeated at each dose. Six potentially useful rating scales and other quantification 
methods are discussed in the final section of this article. 
6. Dosage titration: Start with 10-40 mg propranolol daily in divided doses (10 mg daily 
for small children). For inpatients, monitor standing blood pressure and heart rate 
daily. For outpatients, monitoring should be obtained every 7-14 days, or at each dose 
increase (whichever involves more intensive monitoring). Dosage can be increased 
every 3 days by 10-30 mg/day for closely monitored inpatients, or every 4-7 days for 
outpatients. 
7. Heart rate needs to be monitored at each medical visit, and may limit dose elevation. 
Whenever the pulse is below 50 (adults and older adolescents) or 60 (younger 
adolescents and children), the next dose should be skipped and the daily dosage 
re-evaluated. 
8. Blood pressure also requires close monitoring, and may also limit dosage. Coffey 
(1990) and Kupperman and Stewart (1987) have recommended holding a dose if the 
blood pressure drops below 90/60. This is also the recommended threshold for blood 
pressure in adults (Ayd 1985, Neppe 1990) and undoubtedly applies to adolescents. 
However, we suspect that small children could safely tolerate a slightly lower 
pressure. 
9. Keep in mind that patients with brain damage, mental retardation, or developmental 
disorders may be much more sensitive to low doses of psychotropic agents than are 
patients with normal brain structure or normal IQ. Also, variations in genetic enzyme 
and hepatic biotransformation rates may cause further deviations from standard 
dosing regimens. 
10. Titrate the dosage upward until the appearance of intolerable side effects (usually 
cardiovascular signs) or clinical improvement. Although doses of propranolol 
approaching 1000 mg have been recommended for adults with normal IQ, our 
literature review (Table 1) suggests a mean and median optimal daily dose about 200 
mg (range 30-420 mg) in adult patients with mental retardation or developmental 
disorders, and probably below 150 mg daily in children with MR. Reported daily 
doses of nadolol, whose half-life is longer and which requires less frequent dosing, are 
about half the daily doses of propranolol. 
11. Hold the maximum tolerated dose for at least 4 weeks before considering a trial of a 
β-blocker to be a failure. 
12. It is common practice to add a β-blocker to another psychtropic agent, usually a 
psychopharma-cological treatment already in progress. The available literature 
supports that this is more efficacious than using it alone. However, plasma levels of 
neuroleptics, anticonvulsants, and antidepressants may increase severalfold with 
addition of propranolol. Special caution should be exercised with thioridazine because 
of the risk of pigmentary retinopathy. 
13. When a ß-blocker is discontinued, taper it over a 2-week period to prevent rebound 
tachycardia. 
14. After a patient has been successfully maintained for a substantial period of time, 
consideration should be given to cautious gradual "weaning" to see if the patient can 
maintain the improvement with a lower dose or possibly even discontinuation. If 
deterioration occurs, the previous effective dose should be resumed. 
Empirical Trials of β-Blockers in Mental Retardation or Developmental 
Disorders 
The existing research suggests that a definite role has not yet been established for 
the use of β-blockers for treating patients of any age who have mental retardation or other 
developmental disorders. However, there are sufficient suggestions of efficacy to warrant 
empirical clinical trials in patients with mental retardation or developmental disorders 
when other treatments (e.g., behavior modification, neuroleptics, lithium carbonate) have 
been unsuccessful. In this population, β-blockers appear to be helpful in managing some 
patients with severe verbal or physical aggressive or self-injurious behavior, and 
speculatively with severe anxiety or hyperactivity. Empirical trials should be undertaken 
with a data collection method that enables informed decisions to be made about the 
usefulness of treatment. 
Methods of assessment 
The two principal sources of empirical data when conducting clinical drug trials are 
target behavior observation and rating scales (see Aman and White 1986). 
Target Behavior Observations. 
Direct observation of the behaviors of concern (e.g., aggressive episodes) may 
entail measures of response duration (as in tantrums), interval recording, frequency counts, 
or momentary time sampling (Aman and White 1986). 
In measuring response duration, every instance of the target behavior is actually 
timed, usually with a stopwatch. Interval recording involves dividing the observational 
period into numerous intervals of equal length. The observer's task is to note whether or not 
each target behavior occurs within each interval over time. This results in an occurrence 
measure (a percentage of time intervals) for each of the behavioral categories. Interval 
recording is probably the most frequently used form of direct observation for assessing 
psychotropic drugs, and has the best-researched methods for determining its reliability 
(Aman and White 1986). Frequency counts entail the systematic recording of all 
occurrences of the target behavior over standard units of time. Momentary time sampling 
(also called point sampling) involves the brief observation of behavior at regular or 
randomized intervals (e.g., every 20 minutes) and the recording of all observational 
categories that are occurring at that moment. 
Response duration is most suitable for behaviors of relatively long duration, such as 
on-task behavior and screaming bouts. Frequency counts are most suitable for assessing 
low-rate discrete behaviors, such as fighting, that may not be detected in short 
observational sessions (Aman and White 1986). Momentary time sampling can be 
relatively cost effective and may be preferred when the target behaviors vary widely over 
the course of the day. 
All forms of direct observation entail the formulation of explicit behavioral 
definitions of what the patient must do (or not do) in order to be scored positive for the 
behavior. Most developmental centers and group homes have behavioral specialists who 
assist in collecting such information. 
Rating Scales. 
Several well-validated behavior rating scales might be considered. The Social 
Dysfunction and Aggression Scale (SDAS) is an observer-completed form that includes 9 
items concerning outward aggression and 2 items related to inward aggression (Wistedtet 
al. 1990). The Overt Aggression Scale (OAS) permits each episode of aggressive behavior 
to be scored on one of four ordinal subscales: (1) verbal aggression, (2) physical aggression 
toward objects, (3) physical aggression toward self, and (4) physical aggression against 
other people (Yudofsky et al. 1986). The Staff Observation Aggression Scale (SOAS) is an 
instrument for quantifying specific aggressive acts on three relevant dimensions: (1) 
method used in committing the aggression, (2) the aim of the aggression, and (3) the 
consequences of the aggression (Palmstierna and Wistedt 1987). However, all of these 
instruments (SDAS, OAS, SOAS) were developed for nonretarded clinical populations 
and, to the best of our knowledge, their applicability in mental retardation and 
developmental disorders has not been well studied. Also, the SOAS does not have adequate 
sections to monitor self-injurious behavior. 
In a recent exhaustive review of the available instruments for assessing behavior 
disorders in mental retardation (Aman 1991), the Behavior Problems Inventory (BPI) 
emerged as one of the more suitable instruments for assessing aggression and self-injury 
(Rojahn 1989,Rojahnetal. 1989). The BPI comprises 15 self-injurious behavior items, 5 
Stereotypie behavior items, and 9 aggressive behavior items. Raters are asked to determine 
whether a given item applies to a patient and, if so, to rate its frequency on a 6-point scale 
from 1 (less than monthly) to 6 (more than once per hour). 
Another important option is the Aberrant Behavior Checklist (ABC), a 
general-purpose rating scale that was specifically developed for assessing treatment effects 
in mentally retarded people (Aman and Singh 1986, Aman et al. 1985a, 1985b). The ABC 
encompasses 58 items that load onto five subscales: (1) irritability, agitation, crying (15 
items); (2) lethargy, social withdrawal (16 items); (3) Stereotypie behavior (7 items); (4) 
hyperactivity, noncompliance (16 items); (5) inappropriate speech (4 items). This 
instrument has been shown to be very sensitive to the effects of a variety of psychotropic 
drugs. Incorporating the ABC in any pharmacological evaluation would be particularly 
helpful in determining how behaviors other than aggression and self-injury are affected. 
Finally, the Self-Injurious Behavior Questionnaire has been released (Gualtieri and 
Schroeder 1989), but published data on its psychometric properties are not yet available. 
These and other instruments reviewed in the Aman (1991) monograph will be discussed in 
a future paper to appear in the Mental Retardation section of this Journal. 
In summary, since the evidence supporting the efficacy of ß-blockers in mental 
retardation or developmental disorders in children and adolescents is not definitive, the 
clinician is well advised to design an empirical trial for each patient, utilizing pre- and 
postmedication measures. Many questions remain unanswered, including the possibility of 
IQ-related differences in drug réponse (e.g., efficacy, dose requirements, or adverse 
effects) and the possible clinical value of peripherally acting medications. We hope that 
controlled studies of β-adrenergic blocking agents in the management of children and 
adolescents with mental retardation and developmental disorders will be forthcoming 
soon. 
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